Clinical Trials at University of Oklahoma Health Sciences Center

As of June 2026, 206 paid clinical trials are recruiting at University of Oklahoma Health Sciences Center, located at 1200 N PHILLIPS AVE, SUITE 12109, OKLAHOMA CITY, OK 73104-4600, phone (405) 271-8685 in Oklahoma City, Oklahoma. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: June 12, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

206 clinical trials at University of Oklahoma Health Sciences Center

·Clear filters·↓ Download CSV

Autoimmune Basis for Postural Tachycardia Syndrome

for Postural Orthostatic Tachycardia Syndrome

2 locations incl. Oklahoma City

Sponsor: Vanderbilt University Medical Center

Sex: All·Age: 18 - 50·Accepts healthy volunteers

Code: NCT02725060·Enrolling By Invitation

Project: Every Child for Younger Patients With Cancer

for Adrenal Gland Pheochromocytoma

245 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 25

Code: NCT02402244·Recruiting

Apply to this trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

for Intracranial Meningioma

780 locations incl. Birmingham

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT02523014·Phase 2·Recruiting

Apply to this trial

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

for Hodgkin Lymphoma in Remission

69 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT01790152·Recruiting

Apply to this trial

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

for Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma

Drug: Atezolizumab

338 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT01810913·Phase 2, Phase 3·Recruiting

Apply to this trial

Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women

for Ovarian Cancer

12 locations incl. Miami

Sponsor: M.D. Anderson Cancer Center

Sex: Female·Age: 50 - 74·Accepts healthy volunteers

Code: NCT00539162·Recruiting

Apply to this trial